0001415889-24-010509.txt : 20240408 0001415889-24-010509.hdr.sgml : 20240408 20240408172025 ACCESSION NUMBER: 0001415889-24-010509 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240404 FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ragosa Mark CENTRAL INDEX KEY: 0001835458 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 24830499 MAIL ADDRESS: STREET 1: C/O KINIKSA PHARMACEUTICALS CORP. STREET 2: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 BUSINESS PHONE: 7814399100 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 form4-04082024_090417.xml X0508 4 2024-04-04 0001730430 Kiniksa Pharmaceuticals, Ltd. KNSA 0001835458 Ragosa Mark C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM 11 BERMUDA false true false false CHIEF FINANCIAL OFFICER 0 Class A Common Share 2024-04-08 4 M 0 2694 A 19562 D Class A Common Share 2024-04-08 4 F 0 791 17.90 D 18771 D Share Option 18.06 2024-04-04 4 A 0 33150 0 A 2034-03-31 Class A Common Share 33150 33150 D Performance Share Unit 2024-04-04 4 A 0 5092 0 A 2034-03-31 Class A Common Share 5092 5092 D Restricted Share Unit 2024-04-04 4 A 0 6365 0 A Class A Common Share 6365 11615 D Restricted Share Unit 2024-04-08 4 M 0 2694 0 D Class A Common Share 2694 8921 D Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024. Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date April 1, 2024. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. /s/ Madelyn Zeylikman, Attorney-in-Fact 2024-04-08